These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33420219)

  • 1. Salivary microbiome with gastroesophageal reflux disease and treatment.
    Kawar N; Park SG; Schwartz JL; Callahan N; Obrez A; Yang B; Chen Z; Adami GR
    Sci Rep; 2021 Jan; 11(1):188. PubMed ID: 33420219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux-A Prospective Longitudinal Interventional Study.
    Castellani C; Singer G; Kashofer K; Huber-Zeyringer A; Flucher C; Kaiser M; Till H
    Front Cell Infect Microbiol; 2017; 7():444. PubMed ID: 29075620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease.
    Shi YC; Cai ST; Tian YP; Zhao HJ; Zhang YB; Chen J; Ren RR; Luo X; Peng LH; Sun G; Yang YS
    Genomics Proteomics Bioinformatics; 2019 Feb; 17(1):52-63. PubMed ID: 31028880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Microbiota and Inorganic Anion Content in the Saliva of Patients with Gastroesophageal Reflux Disease and Gastroesophageal Reflux Disease-Free Individuals.
    Ziganshina EE; Sagitov II; Akhmetova RF; Saleeva GT; Kiassov AP; Gogoleva NE; Shagimardanova EI; Ziganshin AM
    Biomed Res Int; 2020; 2020():2681791. PubMed ID: 32509854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of salivary pepsin measurement in patients with proton pump inhibitor-refractory gastroesophageal reflux disease symptoms: a prospective comparative study.
    Matsumura T; Arai M; Suzuki T; Hoppo T; Seki Y; Kasamatsu S; Ishigami H; Ishikawa K; Okimoto K; Akizue N; Maruoka D; Nakagawa T; Odaka T; Okamoto Y; Kato N
    Esophagus; 2020 Jul; 17(3):339-347. PubMed ID: 31982992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The dental status of patients with gastroesophageal reflux disease depending on the intake of proton pump inhibitors].
    Sazanskaya LS; Gulua MM; Gilmiyarov EM; Margaryan EG
    Stomatologiia (Mosk); 2020; 99(5):25-31. PubMed ID: 33034173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis.
    Chen CH; Lin CL; Kao CH
    Osteoporos Int; 2016 Jun; 27(6):2117-26. PubMed ID: 26860609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Yadlapati R; DeLay K
    Med Clin North Am; 2019 Jan; 103(1):15-27. PubMed ID: 30466671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study.
    Foocharoen C; Chunlertrith K; Mairiang P; Mahakkanukrauh A; Suwannaroj S; Namvijit S; Wantha O; Nanagara R
    Sci Rep; 2020 Jan; 10(1):769. PubMed ID: 31964957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study.
    Isshi K; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Ogawa M; Arihiro S; Haruma K; Nakada K
    J Gastroenterol; 2019 Jun; 54(6):492-500. PubMed ID: 30673836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volume, distribution and acidity of gastric secretion on and off proton pump inhibitor treatment: a randomized double-blind controlled study in patients with gastro-esophageal reflux disease (GERD) and healthy subjects.
    Steingoetter A; Sauter M; Curcic J; Liu D; Menne D; Fried M; Fox M; Schwizer W
    BMC Gastroenterol; 2015 Sep; 15():111. PubMed ID: 26328588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
    Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
    J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reasons for proton-pump-inhibitor failure in the treatment of gastroesophageal reflux disease].
    Juhász M; Tulassay Z
    Orv Hetil; 2008 Oct; 149(40):1881-8. PubMed ID: 18815107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between type 2 diabetes mellitus and failure to proton pump inhibitor treatment in gastroesophageal reflux disease.
    Hershcovici T; Jha LK; Gadam R; Cui H; Gerson L; Thomson S; Fass R
    J Clin Gastroenterol; 2012 Sep; 46(8):662-8. PubMed ID: 22858518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
    Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
    Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients.
    Rinsma NF; Farré R; Bouvy ND; Masclee AA; Conchillo JM
    Neurogastroenterol Motil; 2015 Feb; 27(2):220-8. PubMed ID: 25348594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unmet treatment needs of gastroesophageal reflux disease in Asia: gastroesophageal reflux disease in Asia Pacific survey.
    Goh KL; Choi MG; Hsu WP; Chun HJ; Mahachai V; Kachintorn U; Leelakusolvong S; Kim N; Rani AA; Wong BC; Wu J; Chiu CT; Chu R; Shetty V; Bocobo JC; Chan MM; Lin JT
    J Gastroenterol Hepatol; 2014 Dec; 29(12):1969-75. PubMed ID: 24990817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.